ProShare Advisors
CRNX

ProShare Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

ProShare Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$638K Sell
17,040
-1,816
-10% -$67.5K ﹤0.01% 957
2026
Q1 		$685K Sell
18,856
-1,865
-9% -$83.3K ﹤0.01% 911
2025
Q4 		$965K Buy
20,721
+1,917
+10% +$85.3K ﹤0.01% 824
2025
Q3 		$783K Sell
18,804
-3,236
-15% -$103K ﹤0.01% 897
2025
Q2 		$634K Sell
22,040
-1,998
-8% -$61.7K ﹤0.01% 985
2025
Q1 		$806K Sell
24,038
-5,051
-17% -$189K ﹤0.01% 875
2024
Q4 		$1.49M Buy
29,089
+9,655
+50% +$540K ﹤0.01% 767
2024
Q3 		$993K Buy
19,434
+5,730
+42% +$296K ﹤0.01% 815
2024
Q2 		$614K Sell
13,704
-3,027
-18% -$140K ﹤0.01% 875
2024
Q1 		$783K Buy
16,731
+1,655
+11% +$64.8K ﹤0.01% 864
2023
Q4 		$536K Buy
15,076
+3,105
+26% +$95.2K ﹤0.01% 996
2023
Q3 		$356K Buy
11,971
+1,540
+15% +$31.7K ﹤0.01% 1114
2023
Q2 		$188K Buy
+10,431
New +$208K ﹤0.01% 1555
2023
Q1 		– Sell
-11,222
Closed -$205K – 1817
2022
Q4 		$205K Buy
11,222
+913
+9% +$16.1K ﹤0.01% 1482
2022
Q3 		$204K Buy
10,309
+230
+2% +$4.69K ﹤0.01% 1400
2022
Q2 		$188K Sell
10,079
-3,480
-26% -$69.5K ﹤0.01% 1491
2022
Q1 		$298K Sell
13,559
-3,196
-19% -$64.7K ﹤0.01% 1634
2021
Q4 		$476K Buy
16,755
+3,721
+29% +$91.7K ﹤0.01% 1484
2021
Q3 		$274K Sell
13,034
-3,183
-20% -$66.6K ﹤0.01% 1611
2021
Q2 		$306K Buy
16,217
+4,431
+38% +$77.9K ﹤0.01% 1883
2021
Q1 		$180K Buy
11,786
+711
+6% +$11K ﹤0.01% 2066
2020
Q4 		$156K Buy
+11,075
New +$154K ﹤0.01% 1909
2019
Q2 		– Sell
-9,098
Closed -$207K – 1632
2019
Q1 		$207K Buy
9,098
+217
+2% +$5.33K ﹤0.01% 1457
2018
Q4 		$266K Buy
+8,881
New +$250K ﹤0.01% 1214

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's CRNX Position: Q2 2026 in Review

ProShare Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 9.6% in Q2 2026, selling an estimated $67.5K and leaving 17,040 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #957.

ProShare Advisors first reported a position in CRNX in Q4 2018 and has held it in 24 quarters since. The position peaked at $1.49M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • ProShare Advisors held 17,040 shares of Crinetics Pharmaceuticals worth $638K as of Q2 2026.
  • ProShare Advisors sold 1,816 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $67.5K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #957 holding.
  • ProShare Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
  • ProShare Advisors's Crinetics Pharmaceuticals position peaked at $1.49M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.